Reston, VA (June 26, 2026)—New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
Summaries of the newly published research articles are provided below.
Breast Cancer Study Explores Somatostatin PET Imaging for Targeted Therapy
Researchers evaluated two somatostatin receptor (SSTR) PET tracers in patients with advanced breast cancer to determine how often tumors expressed SSTR, a potential target for radioligand therapy. The study found SSTR-positive tumors in many estrogen receptor-positive cases but fewer triple-negative cancers, while comparing the performance of agonist and antagonist imaging agents.
Interim PET Scan May Help Track Response to PSMA Therapy in Advanced Prostate Cancer
Researchers evaluated whether an interim 18F-FDG PET/CT scan after three cycles of 177Lu-PSMA therapy could help assess treatment response in advanced prostate cancer. Patients with disease progression or increasing metabolic tumor volume on PET were less likely to achieve substantial PSA declines and experienced shorter progression-free survival.
New PET Tracer Shows Promise for Detecting Staph Infections
Researchers developed and tested a new PET imaging tracer, 18F-FSK, designed to detect active Staphylococcus aureus infections. The tracer showed strong uptake across multiple bacterial strains, favorable distribution in the body, and radiation doses comparable to 18F-FDG, while an improved production method supports future clinical development.
Visit the JNM website for the latest research and follow our Twitter and Facebook
